Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice : recommendations from a Eastern and Southern Europe diabetes expert group
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F22%3A00083455" target="_blank" >RIV/00023001:_____/22:00083455 - isvavai.cz</a>
Výsledek na webu
<a href="https://reader.elsevier.com/reader/sd/pii/S0167527322010853?token=90D01BFA16ACF8D46719F5969CBE8EFEB04924E21464603D84F888DFDAB5B7B432C93CF9E8C44EE3709B31CDE2BAA7FA&originRegion=eu-west-1&originCreation=20230104095811" target="_blank" >https://reader.elsevier.com/reader/sd/pii/S0167527322010853?token=90D01BFA16ACF8D46719F5969CBE8EFEB04924E21464603D84F888DFDAB5B7B432C93CF9E8C44EE3709B31CDE2BAA7FA&originRegion=eu-west-1&originCreation=20230104095811</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ijcard.2022.07.017" target="_blank" >10.1016/j.ijcard.2022.07.017</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice : recommendations from a Eastern and Southern Europe diabetes expert group
Popis výsledku v původním jazyce
Glucagon-like peptide-1 (GLP-1) receptor agonists mimic the action of the endogenous GLP-1 incretin hormone, improving glycaemic control in type 2 diabetes mellitus (T2DM) by increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. However, as cardiovascular (CV) morbidity and mortality is common in patients with T2DM, several trials with the use of GLP-1 receptor agonists (RAs) have been performed focusing on endpoints related to cardiovascular disease rather than metabolic control of T2DM. Following the positive cardiovascular effects of liraglutide, dulaglutide and semaglutide observed in these trials, major changes in T2DM management guidelines have occurred. This document from a Eastern and Southern European Diabetes Expert Group discusses the results of GLP-1 RA CV outcomes trials, their impact on recent clinical guidelines for the management of T2DM, and some selected combination regimens utilising GLP-1 RAs. We also propose an algorithm for guiding GLP-1 RA-based treatment according to patients' characteristics, which can be easily applied in every day clinical practice.
Název v anglickém jazyce
Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice : recommendations from a Eastern and Southern Europe diabetes expert group
Popis výsledku anglicky
Glucagon-like peptide-1 (GLP-1) receptor agonists mimic the action of the endogenous GLP-1 incretin hormone, improving glycaemic control in type 2 diabetes mellitus (T2DM) by increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. However, as cardiovascular (CV) morbidity and mortality is common in patients with T2DM, several trials with the use of GLP-1 receptor agonists (RAs) have been performed focusing on endpoints related to cardiovascular disease rather than metabolic control of T2DM. Following the positive cardiovascular effects of liraglutide, dulaglutide and semaglutide observed in these trials, major changes in T2DM management guidelines have occurred. This document from a Eastern and Southern European Diabetes Expert Group discusses the results of GLP-1 RA CV outcomes trials, their impact on recent clinical guidelines for the management of T2DM, and some selected combination regimens utilising GLP-1 RAs. We also propose an algorithm for guiding GLP-1 RA-based treatment according to patients' characteristics, which can be easily applied in every day clinical practice.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30202 - Endocrinology and metabolism (including diabetes, hormones)
Návaznosti výsledku
Projekt
—
Návaznosti
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Ostatní
Rok uplatnění
2022
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
International journal of cardiology
ISSN
0167-5273
e-ISSN
1874-1754
Svazek periodika
365
Číslo periodika v rámci svazku
October 15
Stát vydavatele periodika
NL - Nizozemsko
Počet stran výsledku
11
Strana od-do
8-18
Kód UT WoS článku
000855639900002
EID výsledku v databázi Scopus
2-s2.0-85135152685